Not logged in Share Save
Share Save
Plain language summary of publication: Comparing nivolumab and neoadjuvant chemotherapy with placebo and neoadjuvant chemotherapy in participants with newly diagnosed estrogen receptor-positive breast cancer in the CheckMate 7FL clinical trial Loi, Sherene; Salgado, Roberto; Curigliano, Giuseppe; Ivan Romero Diaz, Roberto; Delaloge, Suzette; Rojas Garcia, Carlos Ignacio; Kok, Marleen; Saura, Cristina; Harbeck, Nadia; Mittendorf, Elizabeth A.; Yardley, Denise A.; Suarez Zaizar, Alberto; Caminos, Facundo Rufino; Ungureanu, Andrei; Reinoso-Toledo, Joaquin G.; Guarneri, Valentina; Egle, Daniel; Ades, Felipe; Pacius, Misena; Chhibber, Aparna; Chandra, Rajalakshmi; Nathani, Raheel; Spires, Thomas; Qun Wu, Jenny; Pusztai, Lajos; Mcarthur, Heather Share Save
Real-world risk of recurrence and treatment outcomes with adjuvant endocrine therapy in patients with stage II-III HR+/HER2-early breast cancer O'Shaughnessy, Joyce; Tolaney, Sara M.; Yardley, Denise A.; Hart, Lowell; Razavi, Pedram; Fasching, Peter A.; Janni, Wolfgang; Schwartzberg, Lee; Kim, Julia; Akdere, Murat; McDermott, Courtney; Khakwani, Aamir; Pathak, Purnima; Graff, Stephanie L. Share Save
Efficacy and safety of ribociclib (RIB) plus nonsteroidal aromatase inhibitor (NSAI) in older patients (pts) with HR+/HER2-early breast cancer (EBC) in NATALEE Untch, M.; Yardley, D.; Im, S-A.; Pluard, T.; Hart, L.; Crown, J. P.; Freyer, G.; Zamagni, C.; Lopez-Barajas, I. Blancas; Parnizari, F.; Gao, M.; Amin, K.; Hu, H.; Rugo, H. S. Share Save
MORPHEUS Hormone Receptor-Positive Breast Cancer: interim analysis of a Phase Ib/II, study of fulvestrant ± atezolizumab and abemaciclib triplet treatment in patients metastatic disease Jung, Kyung Hae; Im, Seock-Ah; Yardley, Denise; Hurvitz, Sara; Lee, Keun Seok; Sonnenblick, Amir; Shachar, Shlomit; Tan, Antoinette; Comen, Elizabeth; Gal-Yam, Einav; Brufsky, Adam; Rugo, Hope; Zhu, Jing; DuPree, Kelly; Breton, Vanessa; Young, Fiona; Schwab, Richard; Cha, Edward; Telli, Melinda Share Save
Ribociclib (RIB) plus nonsteroidal aromatase inhibitor (NSAI) as adjuvant treatment in patients with HR+/HER2-early breast cancer: final invasive disease-free survival (iDFS) analysis from the NATALEE trial Hortobagyi, Gabriel; Stroyakovsky, Daniil; Yardley, Denise; Huang, Chiun-Shen; Fasching, Peter A.; Crown, John; Bardia, Aditya; Chia, Stephen; Im, Seock-Ah; Martin, Miguel; Loi, Sherene; Xu, Binghe; Hurvitz, Sara; Barrios, Carlos; Untch, Michael; Moroose, Rebecca; Visco, Frances; Parnizari, Federico; Ghaznawi, Farhat; Li, Zheng; Waters, Sorcha; Chakravartty, Arunava; Slamon, Dennis Share Save
Event-free Survival by Residual Cancer Burden (RCB) and Intratumor HER2 Heterogeneity after Neoadjuvant T-DM1 and Pertuzumab for Early-stage HER2-positive Breast Cancer Metzger, Otto; Kim, Se Eun; Tayob, Nabihah; Viale, Giuseppe; Yardley, Denise; Prat, Aleix; Abramson, Vandana; Spring, Laura; Waks, Adrienne; Wrabel, Eileen; Demeo, Michelle; Bardia, Aditya; Dell'Orto, Patrizia; Russo, Leila; King, Tari; Michor, Franziska; Winer, Eric; Polyak, Kornelia; Tolaney, Sara; Krop, Ian Share Save
ACE-Breast-03: A phase 2 study of ARX788, a novel next-generation anti-HER antibody-drug conjugate in HER2-positive metastatic breast cancer patients previously treated with trastuzumab deruxtecan Ali, Kashif; Agrawal, Laila; Thummala, Anu; Kalinsky, Kevin; Ali, Sami; Blau, Sibel; Block, Margaret; Danso, Michael; Yardley, Denise; Andersen, Jay; Gropper-Waks, Adrienne; Jayachandran, Priya; Makhlin, Igor; Nikolinakos, Petros; O'Shaughnessy, Joyce; Aung, Sandra; Hessel, Colin; Rugo, Hope; Gradishar, William; Tripathy, Debu Share Save
Phase I trial of pegylated liposomal doxorubicin chemotherapy in combination with CD40 agonist and Flt3 ligand in metastatic triple-negative breast cancer Reddy, Sangeetha; O'Shaughnessy, Joyce; Sadeghi, Navid; Syed, Samira; Santa-Maria, Cesar; Kaklamani, Virginia; Chen, Nan; Yardley, Denise; Fang, Yisheng; Chan, Isaac; Unni, Nisha; Kashanian, Sarah; Peswani, Namrata; Shakeel, Shahbano; Carter, Meredith; Kyle, Kelly; Fattah, Farjana; Ahn, Chul; Patel, Ina; Gruber, Joshua; Klemow, Dawn; Delgado, Glenda; Sinclair, Nicole; Yellin, Michael; McArthur, Heather; Nanda, Rita; Conzen, Suzanne; Arteaga, Carlos Share Save
Biomarker Results in High-risk Estrogen Receptor Positive, Human Epidermal Growth Factor Receptor 2 Negative Primary Breast Cancer Following Neoadjuvant Chemotherapy ± Nivolumab: an Exploratory Analysis of CheckMate 7FL Loi, Sherene; Curigliano, Giuseppe; Salgado, Roberto; Diaz, Roberto Ivan Romero; Delaloge, Suzette; Garcia, Carlos Ignacio Rojas; Kok, Marleen; Saura, Cristina; Harbeck, Nadia; Mittendorf, Elizabeth; Yardley, Denise; Pusztai, Lajos; Zaizar, Alberto Suarez; Ungureanu, Andrei; Ades, Felipe; Chandra, Rajalakshmi; Nathani, Raheel; Pacius, Misena; Spires, Thomas; Wu, Jenny; McArthur, Heather Share Save
Ribociclib plus Endocrine Therapy in Early Breast Cancer Slamon, Dennis; Lipatov, Oleg; Nowecki, Zbigniew; McAndrew, Nicholas; Kukielka-Budny, Bozena; Stroyakovskiy, Daniil; Yardley, Denise A.; Huang, Chiun-Sheng; Fasching, Peter A.; Crown, John; Bardia, Aditya; Chia, Stephen; Im, Seock-Ah; Ruiz-Borrego, Manuel; Loi, Sherene; Xu, Binghe; Hurvitz, Sara; Barrios, Carlos; Untch, Michael; Moroose, Rebecca; Visco, Frances; Afenjar, Karen; Fresco, Rodrigo; Severin, Irene; Ji, Yan; Ghaznawi, Farhat; Li, Zheng; Zarate, Juan P.; Chakravartty, Arunava; Taran, Tetiana; Hortobagyi, Gabriel Share Save
HER2 heterogeneity and treatment response- associated profiles in HER2-positive breast cancer in the NCT02326974 clinical trial Li, Zheqi; Metzger Filho, Otto; Viale, Giuseppe; dell'Orto, Patrizia; Russo, Leila; Goyette, Marie -Anne; Kamat, Avni; Yardley, Denise A.; Abramson, Vandana Gupta; Arteaga, Carlos L.; Spring, Laura M.; Chiotti, Kami; Halsey, Carol; Waks, Adrienne G.; King, Tari A.; Lester, Susan C.; Bellon, Jennifer R.; Winer, Eric P.; Spellman, Paul T.; Krop, Ian E.; Polyak, Kornelia Share Save
Matching-adjusted indirect comparison of PFS and OS comparing ribociclib plus letrozole versus palbociclib plus letrozole as first-line treatment of HR+/HER2-advanced breast cancer Jhaveri, Komal; O'Shaughnessy, Joyce; Fasching, Peter A.; Tolaney, Sara M.; Yardley, Denise A.; Sharma, Vikash Kumar; Biswas, Chandroday; Thuerigen, Astrid; Pathak, Purnima; Rugo, Hope S. Share Save
Axillary Nodal Response to Neoadjuvant T-DM1 Combined with Pertuzumab in a Prospective Phase II Multi-Institution Clinical Trial Weiss, Anna; Jin, Qingchun; Waks, Adrienne G.; Yardley, Denise; Spring, Laura M.; Wrabel, Eileen; Tayob, Nabihah; Viale, Giuseppe; Krop, Ian E.; King, Tari A.; Metzger-Filho, Otto Share Save
Intrinsic Subtype and Overall Survival of Patients with Advanced HR+/HER2- Breast Cancer Treated with Ribociclib and ET: Correlative Analysis of MONALEESA-2,-3,-7 Prat, Aleix; Solovieff, Nadia; Andre, Fabrice; O'Shaughnessy, Joyce; Cameron, David A.; Janni, Wolfgang; Sonke, Gabe S.; Yap, Yoon-Sim; Yardley, Denise A.; Partridge, Ann H.; Thuerigen, Astrid; Zarate, Juan Pablo; Lteif, Agnes; Su, Fei; Carey, Lisa A. Share Save
Health-related quality of life (HRQoL) in the phase III NATALEE study of adjuvant ribociclib (RIB) plus a nonsteroidal aromatase inhibitor (NSAI) vs NSAI alone in patients (pts) with HRD/HER2-early breast cancer (EBC) Fasching, P. A.; Slamon, D.; Nowecki, Z.; Kukielka-Budny, B. D.; Stroyakovskiy, D.; Yardley, D.; Huang, C.; Chan, A.; Chia, S.; Martin, M.; Rugo, H. S.; Loi, S.; Hurvitz, S. A.; Untch, M.; Afenjar, K.; Fresco, R.; Danyliv, A.; Ferrusi, I.; Li, Z.; Hortobagyi, G. N. Share Save
A randomized, double-blind trial of nivolumab (NIVO) vs placebo (PBO) with neoadjuvant chemotherapy (NACT) followed by adjuvant endocrine therapy (ET) ± NIVO in patients (pts) with high-risk, ER+HER2L primary breast cancer (BC) Loi, S.; Curigliano, G.; Salgado, R. F.; Diaz, R. I. Romero; Delaloge, S.; Rojas, C.; Kok, M.; Manich, C. Saura; Harbeck, N.; Mittendorf, E. A.; Yardley, D.; Pusztai, L.; Zaizar, A. Suarez; Ungureanu, A.; Ades, F.; Chandra, R.; Nathani, R.; Pacius, M.; Wu, J. Q.; McArthur, H. L. Share Save
Endocrine Therapy Synergizes with SMAC Mimetics to Potentiate Antigen Presentation and Tumor Regression in Hormone Receptor-Positive Breast Cancer Hermida-Prado, Francisco; Xie, Yingtian; Sherman, Shira; Nagy, Zsuzsanna; Russo, Douglas; Akhshi, Tara; Chu, Zhengtao; Feit, Avery; Campisi, Marco; Chen, Minyue; Nardone, Agostina; Guarducci, Cristina; Lim, Klothilda; Font-Tello, Alba; Lee, Irene; Garcia-Pedrero, Juana; Canadas, Israel; Agudo, Judith; Huang, Ying; Sella, Tal; Jin, Qingchun; Tayob, Nabihah; Mittendorf, Elizabeth A.; Tolaney, Sara M.; Qiu, Xintao; Long, Henry; Symmans, William F.; Lin, Jia-Ren; Santagata, Sandro; Bedrosian, Isabelle; Yardley, Denise A.; Mayer, Ingrid A.; Richardson, Edward T.; Oliveira, Giacomo; Wu, Catherine J.; Schuster, Eugene F.; Dowsett, Mitch; Welm, Alana L.; Barbie, David; Metzger, Otto; Jeselsohn, Rinath Share Save
Rationale and trial design of NATALEE: a Phase III trial of adjuvant ribociclib plus endocrine therapy versus endocrine therapy alone in patients with HR+/HER2-early breast cancer Slamon, Dennis J.; Fasching, Peter A.; Hurvitz, Sara; Chia, Stephen; Crown, John; Martin, Miguel; Barrios, Carlos H.; Bardia, Aditya; Im, Seock-Ah; Yardley, Denise A.; Untch, Michael; Huang, Chiun-Sheng; Stroyakovskiy, Daniil; Xu, Binghe; Moroose, Rebecca L.; Loi, Sherene; Visco, Frances; Bee-Munteanu, Valerie; Afenjar, Karen; Fresco, Rodrigo; Taran, Tetiana; Chakravartty, Arunava; Zarate, Juan Pablo; Lteif, Agnes; Hortobagyi, Gabriel N. Share Save
.png){kind=icon}
.png){kind=icon}
Not logged in.png){kind=icon}
.png){kind=icon}
.png){kind=icon}
.png){kind=icon}
.png){kind=icon}
